GHRSGH Research PLC
Price
+31%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 7% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for GHRS today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
We are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. Our initial focus is on developing our novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression, or TRD. Our portfolio currently includes GH001, our proprietary inhalable mebufotenin product candidate and GH002, our proprietary intravenous mebufotenin product candidate.
In the company’s own words · 20-F filed Mar 5, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.